Cathepsin B, D and S as Potential Biomarkers of Brain Glioma Malignancy

Abstract

Brain gliomas constitute the vast majority of malignant tumors of the nervous system. There is still a lack of fast, reliable and non-invasive methods of diagnostics. Our work focuses on the quantification of cathepsin B, D and S in glioma. The research was conducted with the use of SPRi biosensors sensitive to individual cathepsins. Changes in the quantity of selected cathepsins (cathepsins B, D and S), depending on the advancement of glioma and the presence or absence of important features or comorbidities in the selected patient, were examined. The results were statistically analyzed and interpreted based on the available clinical description. Statistical significance was observed in the difference in the concentration of the studied cathepsins, mainly between the groups Control and G3/G4 and G1/G2 and G3/G4. The strength of the correlation between the concentrations of individual cathepsins and the age of the patient and the size of the tumor, as well as the correlation between individual proteins, was investigated. The influence of IDH 1/2 status on the concentration of determined cathepsins was investigated and ROC analysis was performed. As a result of our research, we have developed a method for the diagnosis of brain glioma that allows us to distinguish grades G1/G2 from G3/G4 and the control group from G3/G4. We found an average positive correlation between the concentrations of the proteins tested and the age of the patient and a high positive correlation between the cathepsins tested. Comparative analysis of the effect of the presence of IDH 1/2 mutations on the number of proteins tested allowed us to demonstrate that the cathepsins assayed can be independent markers.